top of page

Free Biopharma Daily Stock Updates - 11/22/21

$XBI $119.28 -2.17%

 


Covid Updates

$BNTX +11.0% $PFE +0.8% Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age. source


Pipeline Updates

$TNXP -3.8% Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight source


$GLPG -4.2% Galapagos completes patient recruitment for MANGROVE Phase 2 trial with

GLPG2737 in polycystic kidney disease source


$CRSP -2.2% CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies. source


$ATNX -1.1% Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021. source


$HZNP 1.5% New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD). source


$VSTM -3.4% Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer. source


$NTLA -3.7% Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). source


$MRTX +1.5% Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer. source


$OLMA -6.6% Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium. source


$PRVB +15.00% Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway. source


$AFMD +4.8% Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas. source


$DCPH +1.9% Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. source


$DAWN -5.4% Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors. source


$RGNX +0.6% REGENXBIO ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO RGX-202, A NOVEL GENE THERAPY CANDIDATE FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY. source


$BLUE -1.5% bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions. source


$MNOV -4.4% MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology. source


$OBSV -3.9% Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix. source


$EXEL -4.5% Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021. source


Business Updates

$MRK +1.2% MERCK COMPLETES ACQUISITION OF ACCELERON PHARMA INC. source


$SRNE +2.0% Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market source


$ENDP -1.6% Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting. source


$LTRN -1.2% Lantern Pharma Announces Share Repurchase Program. source


$LNTH +1.2% Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022. source


$NBIX 0.0% Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders. source


$DBTX +0.9% Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss. source


$RFL -7.4% Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus. source


$BCRX +4.7% BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets. source


$ZYNE -2.9% Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™. source


$EVFM +4.6% Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023. source


$HGEN -3.6% Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021. source


$XNCR +1.2% Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor. source


 

Posted by DV/JM

0 comments
bottom of page